Loading
A phase 2 trial of Rinatabart sesutecan in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, now recruiting.
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07288177 by Genmab, with 240 participants planned, started 2026-01-30 and due to reach its primary completion in 2027-11-22. Interventions recorded: Rina-S. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).